2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II

- Gustafsson, Finn, Petrie, Mark C., Fail, Peter S., Chung, Eugene S., Lurz, Philipp, Lilly, Scott, Kaye, David M., Cleland, John G. F., Cikes, Maja, Leon, Martin B., Cutlip, Donald E., van Veldhuisen, Dirk J., Komtebedde, Jan, Solomon, Scott D., Shah, SJ, Swarup, Vijendra, Winkler, Sebastian, Hasenfuß, Gerd, Borlaug, Barry A., Mohan, Rajeev C., Flaherty, James D., Sverdlov, Aaron L.

Association of Circulating Plasma Secreted Frizzled-Related Protein 5 (Sfrp5) Levels with Cardiac Function

- Kelly, Conagh J., Chu, Matthew, Untaru, Rossana, Assadi-Khansari, Bahador, Chen, Dongqing, Croft, Amanda J., Horowitz, John D., Boyle, Andrew J., Sverdlov, Aaron L., Ngo, Doan T. M.

Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

- Shah, Sanjiv J., Borlaug, Barry A., Litwin, Sheldon E., Lurz, Philipp, Massaro, Joseph M., Mohan, Rajeev C., Ricciardi, Mark J., Solomon, Scott D., Sverdlov, Aaron L., Swarup, Vijendra, van Veldhuisen, Dirk J., Winkler, Sebastian, Chung, Eugene S., Leon, Martin B., REDUCE LAP-HF II investigators,, Cutlip, Donald E., Debonnaire, Philippe, Fail, Peter S., Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M.

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

- Lyon, Alexander R., Dent, Susan, Stanway, Susannah, Earl, Helena, Brezden-Masley, Christine, Cohen-Solal, Alain, Tocchetti, Carlo G., Moslehi, Javid J., Groarke, John D., Bergler-Klein, Jutta, Khoo, Vincent, Tan, Li Ling, Anker, Markus S., von Haehling, Stephan, Maack, Christoph, Pudil, Radek, Barac, Ana, Thavendiranathan, Paaladinesh, Ky, Bonnie, Neilan, Tomas G., Sverdlov, Aaron L.

Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic?

- Balachandran, Lohis, Haw, Tatt Jhong, Leong, Angeline Jia Wen, Croft, Amanda J., Chen, Dongqing, Kelly, Conagh, Sverdlov, Aaron L., Ngo, Doan T. M.

Cardiac events among a cohort of 17,389 patients receiving cancer chemotherapy: short and long term implications

- Liu, Saifei, Horowitz, John D., Koczwara, Bogda, Sverdlov, Aaron L., Packer, Natalie, Clark, Robyn A.

Cardiovascular outcomes of cancer patients in rural Australia

- Williams, Trent D., Kaur, Amandeep, Warner, Thomas, Aslam, Maria, Clark, Vanessa, Walker, Rhonda, Ngo, Doan T.M., Sverdlov, Aaron L.

Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology

- Tocchetti, Carlo Gabriele, Farmakis, Dimitrios, Plummer, Chris, Gulati, Geeta, Ramalingam, Sivatharshini, Cardinale, Daniela, Brezden-Masley, Christine, Iakobishvili, Zaza, Thavendiranathan, Paaladinesh, Santoro, Ciro, Bergler-Klein, Jutta, Keramida, Kalliopi, Koop, Yvonne, de Boer, Rudolf A., Maack, C, Lutgens, E, Rassaf, T, Fradley, MG, Moslehi, J, Yang, EH, De Keulenaer, G, Ameri, P, Bax, J, Andres, Maria Sol, Neilan, TG, Herrmann, J, Mbakwem, AC, Mirabel, M, Skouri, H, Hirsch, E, Cohen-Solal, A, Sverdlov, Aaron L., van der Meer, P, Asteggiano, R, Couch, Liam S., Barac, A, Ky, B, Lenihan, D, Dent, S, Seferovic, P, Coats, AJS, Metra, M, Rosano, G, Suter, T, Lopez-Fernandez, T, Formisano, Luigi, Lyon, AR, Ciardiello, Fortunato, Pane, Fabrizio, Au, Lewis, Emmerich, Max

Decreased ATP production and myocardial contractile reserve in metabolic heart disease

- Luptak, Ivan, Sverdlov, Aaron L., Colucci, Wilson S., Panagia, Marcello, Qin, Fuzhong, Pimentel, David R., Croteau, Dominique, Siwik, Deborah A., Ingwall, Joanne S., Bachschmid, Markus M., Balschi, James A.

Early access to a cardio-oncology clinic in an Australian context: a qualitative exploration of patient experiences

- White, Jennifer, Byles, Julie, Williams, Trent, Untaru, Rossana, Ngo, Doan T. M., Sverdlov, Aaron L.

Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)

- Chen, Dongqing, Untaru, Rossana, Stavropoulou, Glykeria, Assadi-Khansari, Bahador, Kelly, Conagh, Croft, Amanda J., Sugito, Stuart, Collins, Nicholas J., Sverdlov, Aaron L., Ngo, Doan T. M.

Energetic dysfunction is mediated by mitochondrial reactive oxygen species and precedes structural remodeling in metabolic heart disease

- Luptak, Ivan, Qin, Fuzhong, Colucci, Wilson S., Sverdlov, Aaron L., Pimentel, David R., Panagia, Marcello, Croteau, Dominique, Siwik, Deborah A., Bachschmid, Markus M., He, Huamei, Balschi, James A.

Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension - Mechanisms and Mitigation

- Butel-Simoes, Lloyd E., Haw, Tatt Jhong, Williams, Trent, Sritharan, Shanathan, Gadre, Payal, Herrmann, Sandra M., Herrmann, Joerg, Ngo, Doan T. M., Sverdlov, Aaron L.

Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction

- Litwin, Sheldon E., Komtebedde, Jan, Sverdlov, Aaron L., Fail, Peter, Chung, Eugene S., Kaye, David M., Blair, John, Eicher, Jean-Christophe, Hummel, Scott L., Zirlik, Andreas, Westenfeld, Ralf, Hayward, Christopher, Hu, Mo, Gorter, Thomas M., Demers, C, Shetty, R, Lewis, G, Starling, RC, Patel, S, Gupta, DK, Morsli, H, Penicka, M, Cikes, M, Burkhoff, Daniel, Gustafsson, F, Silvestry, FE, Rowin, EJ, Cutlip, DE, Leon, MB, Kitzman, DW, Kleber, FX, Shah, SJ, REDUCE LAP-HF Investigators and Research Staff,, Hasenfuß, Gerd, Borlaug, Barry A., Solomon, Scott D., Zile, Michael R., Mohan, Rajeev C., Khawash, Rami

Factors associated with adverse cardiovascular events in cancer patients treated with bevacizumab

- Ngo, Doan T. M., Williams, Trent, Horder, Sophie, Kritharides, Leonard, Vardy, Janette, Mandaliya, Hhiren, Nordman, Ina I. C., Lynam, James, Bonaventura, Tony, Sverdlov, Aaron L.

Fibulin-3 is necessary to prevent cardiac rupture following myocardial infarction

- Murtha, Lucy A., Hardy, Sean A., Birner-Gruenberger, Ruth, Hume, Robert D., Iismaa, Siiri E., Humphreys, David T., Patrick, Ralph, Chong, James J. H., Lee, Randall J., Harvey, Richard P., Graham, Robert M., Rainer, Peter P., Mabotuwana, Nishani S., Boyle, Andrew J., Bigland, Mark J., Bailey, Taleah, Raguram, Kalyan, Liu, Saifei, Ngo, Doan T., Sverdlov, Aaron L., Tomin, Tamara

Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative

- Teske, Arco J., Moudgil, Rohit, Sverdlov, Aaron L., Cheng, Richard K., Makhoul, Silvia, Ghosh, Arjun K., Szmit, Sebastian, Zaha, Vlad, Addison, Daniel, Zhang, Lili, Herrmann, Joerg, Chong, Jun H., López-Fernández, Teresa, Agarwala, Vivek, Iakobishvili, Zaza, Guerrero, Patricia, Yang, Eric H., Leja, Monika, Akhter, Nausheen, Guha, Avirup, Okwuosa, Tochukwu M., Silva, Carolina C., Collier, Patrick, Barac, Ana, DeCara, Jeanne, Bauer, Brenton, Lenneman, Carrie E., Sadler, Diego, Brown, Sherry Ann, Deswal, Anita, Neilan, Tomas G., Ganatra, Sarju, Abdel Qadir, Husam, Menon, Venu

Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers

- Chen, Dongqing, Kelly, Conagh, Haw, Tatt Jhong, Lombard, Janine M., Nordman, Ina I. C., Croft, Amanda J., Ngo, Doan T. M., Sverdlov, Aaron L.

Heart failure outcomes in Aboriginal and Torres Strait Islander peoples in the Hunter New England region of New South Wales

- McGee, Michael, Sugito, Stuart, Sverdlov, Aaron L., Boyle, Andrew J., Al-Omary, Mohammed S., Hartnett, Darren, Senanayake, Tharindu, Hales, Kristy, Majeed, Tazeen, Ngo, Doan T. M., Oakley, Patrick, Leitch, James W.

Ibrutinib-related atrial fibrillation: a single center Australian experience

- Ezad, Saad, Khan, Arshad A., Cheema, Hooria, Ashraf, Asma, Ngo, Doan T. M., Sverdlov, Aaron L., Collins, Nicholas J.